Evaluation of Congestion at Hospital Discharge in Adults with Acute Heart Failure

What this Trial Is About

Acute heart failure AHF is a serious health issue with a high risk of death or hospital readmission within three months after discharge. This risk increases when fluid buildup in the body is not adequately reduced by the end of the hospital stay, as measured by clinical scores, blood tests, or ultrasound scans. Although implantable devices can help guide treatment to reduce lung congestion, current methods to assess congestion lack standardization, making treatment adjustments mostly trial and error. This trial aims to find the best way to evaluate congestion in patients recovering from acute heart failure. Patients hospitalized for acute heart failure will receive several evaluations before discharge, including clinical exams focused on congestion and various Doppler ultrasounds of the heart, lungs, abdomen, neck veins, and kidneys, along with liver elastography. Blood samples will be taken for biological tests and storage. After leaving the hospital, participants will have telephone follow-ups at 3, 12, and 24 months. Quality of life will be assessed using the Kansas City Cardiomyopathy Questionnaire at discharge and during follow-up visits. Throughout the study, researchers will monitor outcomes such as death rates, hospital readmissions, and intravenous diuretic treatments at 3, 12, and 24 months after discharge. They will also assess heart function, kidney function, plasma volume, liver health, and patient quality of life. The study involves detailed clinical, imaging, and laboratory assessments to understand congestion better and how it relates to patient outcomes over a two-year period.

Acute Heart Failure - COngestion Discharge Evaluation